You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GLP-1RA

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Obesity, Liver Diseases, Liver Fibrosis Trial in Boston (ESG, GLP1-RA)

Not yet recruiting
  • Obesity
  • +16 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Nov 14, 2023

GLP-1 Receptor Agonists on Efficacy and Persistence, Adherence

Completed
  • Type 2 Diabetes
  • Obesity
  • GLP-1RA
  • +3 more
  • Valencia, Spain
    INCLIVA
Sep 6, 2022

Type 1 Diabetes Trial in Kuwait City (drug, other, procedure)

Not yet recruiting
  • Type 1 Diabetes
  • Liraglutide / Semaglutide
  • +4 more
  • Kuwait City, Al Asimah, Kuwait
    Dasman Diabetes Institute
Jan 8, 2023

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Recruiting
  • Type 2 Diabetes Mellitus
  • Cardiovascular Diseases
  • Oakland, California
  • +5 more
Oct 18, 2022

Type 2 Diabetes, Diabetes, Type 2 Trial (Tirzepatide)

Not yet recruiting
  • Type 2 Diabetes
  • Diabetes Mellitus, Type 2
  • (no location specified)
Feb 6, 2023

Cystic Fibrosis, Cystic Fibrosis-related Diabetes Trial in Minneapolis (Semaglutide)

Not yet recruiting
  • Cystic Fibrosis
  • Cystic Fibrosis-related Diabetes
  • Minneapolis, Minnesota
    University of Minnesota
Mar 15, 2023

Glucagon-Like Peptide-1 Receptor, Metformin, Obesity, Abdominal Trial in Shanghai (Liraglutide, Semaglutide, Metformin)

Recruiting
  • Glucagon-Like Peptide-1 Receptor
  • +7 more
  • Shanghai, Shanghai, China
    Ren Ji Hospital, Shanghai Jiao Tong University School of Medicin
Mar 9, 2023

Severe Obesity Trial in Minneapolis (Weight loss with pharmacotherapy, Weight loss without pharmacotherapy)

Completed
Has Results
  • Severe Obesity
  • Weight loss with pharmacotherapy
  • Weight loss without pharmacotherapy
  • Minneapolis, Minnesota
    University of Minnesota
Dec 1, 2021

Cardiovascular Diseases, Diabetes Trial in Boston (SGLT2 inhibitor, GLP-1 RA, Education-First)

Completed
  • Cardiovascular Diseases
  • Diabetes
  • SGLT2 inhibitor, GLP-1 RA
  • Education-First
  • Boston, Massachusetts
    Brigham and Women's Hospital
Sep 13, 2023

Diabetes, Diabetic Kidney Disease Trial in Sha Tin (Dulaglutide, Insulin Degludec, Continuous glucose monitor)

Recruiting
  • Diabetes Mellitus
  • Diabetic Kidney Disease
  • Sha Tin, Hong Kong
    Prince of Wales Hospital
Nov 8, 2022

Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility Trial (Intervention to address diffusion of responsibility,

Not yet recruiting
  • Diabetes
  • +3 more
  • Intervention to address diffusion of responsibility
  • Intervention to address diffusion of responsibility + simplification of prescribing
  • (no location specified)
Jul 14, 2022

Chronic Kidney Diseases Trial in Nashville (dulaglutide injection)

Recruiting
  • Chronic Kidney Diseases
  • dulaglutide injection
  • Nashville, Tennessee
    Vanderbilt University Medical Center
Mar 20, 2022

Based on Data From German Sick Funds That Looks at Costs of

Completed
  • Diabetes Mellitus, Type 2
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
Jan 18, 2022

Replication of SEPRA Diabetes Trial in Healthcare Claims Data

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • New use of semaglutide injection
  • New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
  • Boston, Massachusetts
    Brigham and Women's Hospital
Oct 10, 2022

Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism Trial in Barcelona (Experimental: GLP1-RA (exenatide)

Recruiting
  • Hypopituitarism
  • +7 more
  • Experimental: GLP1-RA (exenatide) administration
  • Control: Placebo administration
  • Barcelona, Spain
    Hospital de la Santa Creu i Sant Pau
Mar 18, 2022

Diabetes, Type 2, Cardiovascular Diseases Trial in Louisville (Educational Intervention)

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • Educational Intervention
  • Louisville, Kentucky
    Humana
May 13, 2022

A Pan-European Post-Authorisation Safety Study: Risk of

Not yet recruiting
  • Pancreatic Cancer
  • Exenatide
  • Non-GLP-1 RA based glucose lowering drugs
  • (no location specified)
Dec 21, 2022

Diabetes, Type 2 Trial in United States (LY3457263, Placebo, Dulaglutide)

Recruiting
  • Diabetes Mellitus, Type 2
  • Anniston, Alabama
  • +4 more
Dec 8, 2022

Type 2 Diabetes Trial in Doral (RGT001-075, Placebo)

Active, not recruiting
  • Type 2 Diabetes Mellitus
  • Doral, Florida
    Axon Clinical Research
May 17, 2022

Metabolic Disturbance, Schizophrenia, Type 2 Diabetes Trial in Copenhagen (Semaglutide, 1.34 mg/mL, Semaglutide-)

Not yet recruiting
  • Metabolic Disturbance
  • +5 more
  • Semaglutide, 1.34 mg/mL
  • Semaglutide-placebo
  • Copenhagen, Denmark
    Psychiatric Center Copenhagen, Rigshospitalet
Jun 30, 2021

Type 2 Diabetes Trial in Copenhagen (Endurance exercise training, Semaglutide)

Recruiting
  • Type 2 Diabetes
  • Copenhagen, Denmark
    Xlab, Center for Healthy Aging, Department of Biomedical Science
Feb 8, 2021

Four Second Line Pharmacological Strategies in Type 2 Diabetes

Active, not recruiting
  • Cardiovascular Events
  • +2 more
  • SGLT2 inhibitor
  • +3 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Feb 17, 2022

Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)

Recruiting
  • Diabetes
  • Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
  • Nanjing, China
    Nanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Diabetes, Type 2 Trial in Kuwait (GLP-1 receptor agonist)

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Kuwait, Kuwait
    Dasman Diabetes Institute
Jul 19, 2020